A Chinese drugmaker has developed a biosimilar version of Novo Nordisk’s popular diabetes drug Ozempic and filed for approval. This is according to a report by Hangzhou Jiuyuan Genetic Engineering on Wednesday. In its official social media account, it said the drug application, called Jiyoutai, is designed to control blood sugar levels in patients with type 2 diabetes.